{
  "abstract": "Among the androgen receptor targeted agents (ARTAs) used to treat prostate cancer, enzalutamide1 is a valid option at several stages of the disease. In terms of its drug–drug interaction2 (DDI) profile, it is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19, and in vitro data indicate that it can be an inhibitor of the efflux transporter P-glycoprotein (P-gp). DDIs with apixaban and rivaroxaban (dual substrates of CYP3A4 and P-gp) and digoxin (P-gp substrate) seem to be well characterised.",
  "authors": [
    {
      "affiliations": [
        "Pharmacy, University Hospital Lucus Augusti, Lugo, Galicia, Spain"
      ],
      "name": "Ana Isabel Cachafeiro Pin"
    },
    {
      "affiliations": [
        "Pharmacy, Hospital Da Costa, Burela, Galicia, Spain"
      ],
      "name": "Lucía Grandío Leivas"
    },
    {
      "affiliations": [
        "Urology Department, University Hospital Lucus Augusti, Lugo, Galicia, Spain"
      ],
      "name": "Francisco Caramés Masana"
    },
    {
      "affiliations": [
        "Radiation Oncology Department, University Hospital Lucus Augusti, Lugo, Galicia, Spain"
      ],
      "name": "Alicia Folgar Torres"
    },
    {
      "affiliations": [
        "Radiation Oncology Department, University Hospital Lucus Augusti, Lugo, Galicia, Spain"
      ],
      "name": "Maria Alejandra Naranjo Sánchez"
    }
  ],
  "title": "Colchicine–enzalutamide interaction: clinical implications and multi-disciplinary management",
  "uid": "480514f3-96c7-5069-b5b3-7855f7b44d3d"
}